Abstract:Introduction: The overexpression of ATP-binding cassette (ABC) transporters, ABCB1 and ABCG2, are two of the major mediators of multidrug resistance (MDR) in cancers. Although multiple ABCB1 and ABCG2 inhibitors have been developed and some have undergone evaluation in clinical trials, none have been clinically approved. The compound, MK-2206, an inhibitor of the protein kinases AKT1/2/3, is undergoing evaluation in multiple clinical trials for the treatment of certain types of cancers, including those resistant to erlotinib. In this in vitro study, we conducted in vitro experiments to determine if MK-2206 attenuates multidrug resistance in cancer cells overexpressing the ABCB1 or ABCG2 transporter. Methodology: The efficacy of MK-2206 (0.03-1 μM), in combination with the ABCB1 transporter sub-strates doxorubicin and paclitaxel, and ABCG2 transporter substrates mitoxantrone, SN-38 and topotecan, were determined in the cancer cell lines, KB-C2 and SW620/Ad300, which overexpress the ABCB1 transporter or H460/MX20 and S1-M1-80, which overexpress the ABCG2 transporter, respectively. The expression level and the localization of ABCG2 transporter on the cancer cells membranes were determined using western blot and immunofluorescence assays, respectively, following the incubation of cells with MK-2206. Finally, the interaction between MK-2206 and human ABCG2 transporter was predicted using computer-aided molecular modeling. Results: MK-2206 significantly increased the efficacy of anticancer compounds that were substrates for the ABCG2 but not the ABCB1 transporter. MK-2206 alone (0.03-1 μM) did not significantly alter the viability of H460/MX20 and S1-M1-80 cancer cells, which overexpress the ABCG2 transporter, compared to cells incubated with vehicle. However, MK-2206 (0.3 and 1 μM) significantly increased the anticancer efficacy of mitoxantrone, SN-38 and topotecan, in H460/MX20 and S1-M1-80 cancer cells, as indicated by a significant decrease in their IC50 values, compared to cells incubated with vehicle. MK-2206 significantly increased the basal activity of the ABCG2 ATPase (EC50 = 0.46 μM) but did not significantly alter its expression level and sub-localization in the membrane. The molecular modeling results suggested that MK-2206 binds to the active pocket of the ABCG2 transporter, by a hydrogen bond, hydrophobic interactions and π-π stacking. Conclusion: These in vitro data indicated that MK-2206 surmounts resistance to mitoxantrone, SN-38 and topotecan in cancer cells overexpressing the ABCG2 transporter. If these results can be translated to humans, it is possible that MK-2206 could be used to surmount MDR in cancer cells overexpressing the ABCG2 transporter.

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

The P21-Dependent Radiosensitization Of Human Breast Cancer Cells By Mln4924, An Investigational Inhibitor Of Nedd8 Activating Enzyme

PD-L1 Induction Via the MEK-JNK-AP1 Axis by a Neddylation Inhibitor Promotes Cancer-Associated Immunosuppression

Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells

Dual-target MDM2/MDMX Inhibitor Increases the Sensitization of Doxorubicin and Inhibits Migration and Invasion Abilities of Triple-Negative Breast Cancer Cells Through Activation of TAB1/TAK1/p38 MAPK Pathway.

Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer

The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects Against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-dependent Autophagic, but Not Apoptotic Cell Death Pathway.

Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

[Treatment of Triple Negative Breast Cancer Cells with Combination of Mtor1/2 Inhibitor AZD8055 and MEK1/2 Inhibitor PD0325901].

Data from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

The Chk1 Inhibitor MK-8776 Increases the Radiosensitivity of Human Triple-Negative Breast Cancer by Inhibiting Autophagy.

Neural Precursor Cell Expressed, Developmentally Downregulated 8-Activating Enzyme Inhibitor Mln4924 Sensitizes Colorectal Cancer Cells to Oxaliplatin by Inducing Dna Damage, G2 Cell Cycle Arrest and Apoptosis

Nattokinase Enhances the Sensitivity of Cancer Cells to Oxaliplatin Through Mitochondrial Pathway and Induction of Apoptosis

Combined Aurora Kinase A and CHK1 Inhibition enhances radiosensitivity of triple-negative breast cancer through induction of apoptosis and mitotic catastrophe associated with excessive DNA damage

CRISPR/Cas9 Screening Identifies a Kinetochore‐microtubule Dependent Mechanism for Aurora‐A Inhibitor Resistance in Breast Cancer

Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma

Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy

A Novel Cinnamide Ylt26 Induces Breast Cancer Cells Apoptosis Via Ros-Mitochondrial Apoptotic Pathway In Vitro And Inhibits Lung Metastasis In Vivo